TC BioPharm Addresses Misinformation
TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a pioneering clinical-stage biotechnology venture focused on gamma-delta T cell therapies, recently confronted a wave of misinformation circulating on social platforms. The company firmly asserted that it has compelling compliance with all Nasdaq listing requirements and will persist in trading there with confidence.
The False Rumor
A rumor that gained traction online suggested that TC BioPharm had filed an 8-K Notice to delist from Nasdaq and transition to another trading platform. TC BioPharm quickly dispelled this claim, emphasizing that it operates within the guidelines of the Nasdaq requirements, and there is absolutely no intention to withdraw from the exchange.
Commitment to Transparency
The company reassured its investors and stakeholders that it would actively pursue measures to counteract and safeguard itself against such baseless rumors, which are seen as attempts to undermine its market position. This proactive approach showcases TC BioPharm's commitment to transparency and stability in its operations.
Understanding Gamma-Delta T Cell Therapies
At the forefront of cancer treatment research, TC BioPharm focuses on the development and application of gamma-delta T cell therapies. These innovative therapies leverage the body’s naturally occurring immune cells, known for their dual abilities to engage both innate and adaptive immunity, enabling them to distinguish unhealthy tissues from healthy ones.
Clinical Advancements
As an industry leader, TC BioPharm is notable for being the first company to conduct Phase II clinical studies in oncology related to gamma-delta T cell therapies. Their efforts are underscored by ongoing clinical trials, specifically a pivotal Phase 2b/3 trial targeting acute myeloid leukemia using their proprietary allogeneic CryoTC technology, allowing them to supply frozen therapies to medical facilities globally.
Looking Ahead
As TC BioPharm navigates the current landscape marked by misinformation, its emphasis on rigorous research and compliance positions it well for future endeavors in the biotechnology sector. Stakeholders can remain assured of the company’s stability and ongoing commitment to pioneering innovations in cancer treatment.
Direct Communication Channels
For any inquiries or concerns, TC BioPharm encourages direct communication with its team to ensure clarity and provide answers to stakeholders' questions.
Frequently Asked Questions
What steps is TC BioPharm taking regarding the rumor?
TC BioPharm is actively taking measures to counteract the misinformation and has reassured its stakeholders of its Nasdaq compliance.
What are gamma-delta T cell therapies?
Gamma-delta T cell therapies utilize immune cells that can target and differentiate between healthy and diseased tissues, playing a critical role in cancer treatment.
What is the current status of TC BioPharm's clinical trials?
TC BioPharm is conducting a Phase 2b/3 pivotal trial focused on treating acute myeloid leukemia with its innovative CryoTC technology.
How does TC BioPharm ensure transparency?
TC BioPharm commits to transparency by promptly addressing misinformation and directly communicating with stakeholders regarding their queries and concerns.
How can I contact TC BioPharm?
Interested individuals can reach out to TC BioPharm directly through their official communication channels for any questions or additional information.
